#HROW hashtag - Bluesky

#HROW Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication

www.stocktitan.net/news/HROW/harrow-to-init...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

1 month ago

Original post on benzinga.com

Why Ouster Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket Shares of Ouster Inc (NASDAQ: OUST ) rose sharply in pre-market trading after the company reported better-tha...

#PreMarket #Movers #$NEAR #BATL #BURU #CRDO #Gainers #HROW […]

[Original post on benzinga.com]

0 0 0 0

StockTitan

@stocktitan.net

1 month ago

Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance Fourth Quarter, Full-Year 2025 and Selected Highlights: Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year period Full-Year revenue of $272.3 million, a 36% increase over $199.6 million recorded in 2024 GAAP net income of $6.6 million in Q4 2025,

#HROW Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance

www.stocktitan.net/news/HROW/harrow-announc...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Harrow Announces Third Quarter 2025 Financial Results Third-Quarter 2025 and Recent Selected Highlights: Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year period GAAP net income of $1.0 million Adjusted EBITDA of $22.7 million Cash and cash equivalents of $74.3 million as of September 30, 2025 A Media

#HROW Harrow Announces Third Quarter 2025 Financial Results

www.stocktitan.net/news/HROW/harrow-announc...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

Harrow to Acquire Melt Pharmaceuticals Harrow (Nasdaq: HROW) has announced an agreement to acquire Melt Pharmaceuticals, a clinical-stage pharmaceutical company specializing in non-opioid, non-IV sedation therapies. The acquisition's centerpiece is MELT-300, a patented sublingual formulation combining midazolam and ketamine that showed positive Phase 3 results in November 2024.MELT-300 demonstrated statistical superiority over both sublingual midazolam and placebo in the LOUISE study. Harrow plans to submit an NDA in 2027, targeting a 2028 commercial launch. The company will leverage its experience with MKO Melt®, which has been used in over 500,000 cataract surgeries, to enter the multi-billion-dollar U.S. procedural sedation market.

#HROW Harrow to Acquire Melt Pharmaceuticals

www.stocktitan.net/news/HROW/harrow-to-acqu...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

4 Renowned Eye Disease Experts Join Harrow's Investor Day to Share Vision for Ophthalmic Solutions Ophthalmic solutions provider Harrow hosts Sept 26 Investor Day featuring KOLs in dry eye, retinal disease, and surgical sedation. Event showcases commercial portfolio and pipeline developments.

#HROW Harrow Announces Agenda and Speakers for Investor & Analyst Day

www.stocktitan.net/news/HROW/harrow-announc...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

$250 Million Bond Deal: Harrow Secures Major Debt Refinancing at 8.625% Through 2030 Ophthalmic solutions provider Harrow prices $250M senior notes at 8.625%, due 2030. Proceeds to repay $107.5M Oaktree facility and redeem $115.25M existing notes. Closing expected Sept 12.

#HROW Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

www.stocktitan.net/news/HROW/harrow-announc...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Harrow Announces Second-Quarter 2025 Financial Results Harrow (NASDAQ: HROW), a leading ophthalmic solutions provider, reported strong Q2 2025 financial results with total revenues of $63.7 million, up 30% year-over-year. The company achieved GAAP net income of $5.0 million and Adjusted EBITDA of $17.0 million.Key highlights include VEVYE®'s 66% sequential prescription growth with 50,000 new prescriptions and a 3% market share gain. The company secured exclusive U.S. rights to Samsung Bioepis' ophthalmology biosimilars (BYOOVIZ® and OPUVIZ™) and acquired BYQLOVI™ for post-operative inflammation treatment. Harrow maintains its forecast of over $280 million in revenue for 2025, with strong cash position of $53.0 million.The company expanded its VEVYE® Access for All program through a strategic alliance with Apollo Care, adding 500+ pharmacies nationwide.

#HROW Harrow Announces Second-Quarter 2025 Financial Results

www.stocktitan.net/news/HROW/harrow-announc...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

8 months ago

Pomerantz Law Firm Launches Investigation into Harrow, Inc. Investor Claims Investors of Harrow, Inc. are prompted to take action as Pomerantz Law Firm launches an investigation into potential securities fraud.

Pomerantz Law Firm Launches Investigation into Harrow, Inc. Investor Claims #United_States #New_York #Inc. #Pomerantz_Law #Harrow #HROW

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States Samsung Bioepis has partnered with Harrow (NASDAQ: HROW) for the commercialization of two ophthalmology biosimilars in the United States. The agreement covers BYOOVIZ® (ranibizumab-nuna), the first FDA-approved ophthalmology biosimilar, and OPUVIZ™ (aflibercept-yszy).The commercial license will become effective after Biogen's rights transition back to Samsung Bioepis by the end of 2025. BYOOVIZ, approved in September 2021, has been available since June 2022, while OPUVIZ received FDA approval in May 2024. Both biosimilars target conditions including Wet Age-Related Macular Degeneration, Macular Edema, and other eye disorders.

#HROW Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

www.stocktitan.net/news/HROW/samsung-bioepi...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States Harrow (NASDAQ:HROW) has secured exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio through a definitive agreement. The portfolio includes BYOOVIZ® (ranibizumab-nuna), a LUCENTIS biosimilar, and OPUVIZ™ (aflibercept-yszy), an EYLEA biosimilar, for treating retinal diseases.The transition from current commercialization partner Biogen is expected to complete by end of 2025. This strategic acquisition targets a $9 billion U.S. market opportunity in retinal disease treatment, with current anti-VEGF therapies accounting for over $4.2 billion in annual Medicare Part B spending. The deal positions Harrow as a leading full-spectrum ophthalmic pharmaceuticals provider, aiming to improve treatment accessibility and affordability.

#HROW Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

www.stocktitan.net/news/HROW/harrow-enters-...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

8 months ago

Harrow, Inc. Investors Encouraged to Join Fraud Investigation by Schall Law Firm The Schall Law Firm is conducting an investigation into potential fraud surrounding Harrow, Inc. and urges affected investors to participate.

Harrow, Inc. Investors Encouraged to Join Fraud Investigation by Schall Law Firm #United_States #Inc. #Los_Angeles #Schall_Law_Firm #Harrow #HROW

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks in new uptrend with Average Directional Index, Thu Jun 26th - #TRUE #CSWC #ARCA #FBNC #HROW #LE #MBWM #WNW #TSQ #TEN #SBSI #ONL #KN #HNI #CCO - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Breakthrough Post-Surgery Eye Drug BYQLOVI Shows 85% Pain Relief Success, Harrow Secures Rights New ophthalmic steroid targets 7M annual surgeries with superior pain relief and safety profile. First FDA-approved drug in its class since 2010. See clinical data.

#HROW Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

www.stocktitan.net/news/HROW/harrow-acquire...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Harrow Announces First-Quarter 2025 Financial Results Harrow (HROW) reported its Q1 2025 financial results with total revenues of $47.8 million, marking a 38% increase from $34.6 million in Q1 2024. The company's key product VEVYE saw revenues rise to $21.5 million, up 35% from Q4 2024. Despite record cash flow from operations of $19.7 million, Harrow posted a GAAP net loss of $(17.8) million and Adjusted EBITDA of $(2.0) million. The company's VEVYE Access for All program, launched in mid-March, has shown promising results with prescription volumes and prescribers both increasing over 4X. Harrow maintains its 2025 revenue target of over $280 million and continues to seek strategic acquisitions in the ophthalmic pharmaceutical sector.

#HROW Harrow Announces First-Quarter 2025 Financial Results

www.stocktitan.net/news/HROW/harrow-announc...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Harrow Smashes Revenue Records: Q4 Surges 84% with $67M Haul, Targets $280M in 2025 Record $66.8M Q4 revenue caps transformative year for Harrow. Strong product growth and 40%+ expansion forecast signal ambitious 2025 plans. See full financial analysis inside.

#HROW Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

www.stocktitan.net/news/HROW/harrow-announc...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Medicare Grants Premium Reimbursement to Harrow's TRIESENCE - First Preservative-Free Option to Achieve Full Coverage Harrow's TRIESENCE gains exclusive ASP+6% reimbursement across all care settings, becoming the only preservative-free corticosteroid with comprehensive coverage. Full details inside.

#HROW Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

www.stocktitan.net/news/HROW/harrow-announc...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Tue Mar 18th - #USAR #LXEH #FEAM #WKSP #TIGR #SYRS #RDI #NIU #LAZR #IRD #HROW #CFB #ADTX #IHS #FINV - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Harrow Eyes Record $280M Revenue in 2025: Inside the Growth Strategy Harrow forecasts robust $280M+ revenue for 2025, driven by high-margin branded pharmaceuticals. Company maintains strong financial position while completing extended audit process.

#HROW Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

www.stocktitan.net/news/HROW/harrow-provide...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Harrow Slashes VEVYE Dry Eye Treatment to $59: No Insurance Hurdles, Money-Back Guarantee New VEVYE Access program eliminates insurance barriers, offering affordable dry eye treatment at $59 with no prior authorization and free delivery through PhilRx specialty pharmacy.

#HROW Harrow Launches VEVYE® Access for All

www.stocktitan.net/news/HROW/harrow-launche...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Major Breakthrough: Harrow Ends TRIESENCE Shortage Crisis with 5-Year Manufacturing Deal Harrow partners with veteran manufacturer to ensure TRIESENCE supply stability, addressing FDA shortage listing while developing next-generation formulation for 2027 submission.

#HROW Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

www.stocktitan.net/news/HROW/harrow-execute...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with bullish crossover of moving average convergence divergence signal, Mon Feb 10th - #UDMY #PAYS #NRC #MNRO #APTO #BLBD #CTXR #DMLP #FFIE #GSM #HROW #VANI #SSSS #OCFC #KOSS #IKNA #UP #LICY #UP #KOP #HLX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Harrow Launches 'Harrow Cares' Patient Support Program with Cencora Partnership New initiative offers $0 copay assistance for IHEEZO® and TRIESENCE®, streamlined enrollment, and comprehensive support services for retina patients and specialists.

#HROW #COR Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

www.stocktitan.net/news/HROW/harrow-partner...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#HROW OSRX, Inc. Responds to Jury Verdict in Trademark Infringement Case

www.stocktitan.net/news/HROW/osrx-inc-respo...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#HROW Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.

www.stocktitan.net/news/HROW/harrow-s-impri...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#HROW Harrow Announces Participation in Upcoming Investor Conferences

www.stocktitan.net/news/HROW/harrow-announc...

0 0 0 0